A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Semaglutide — the active ingredient in Ozempic®, Wegovy®, and Rybelsus® — can reduce your appetite and curb food cravings to ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

PS makes wellness more accessible through real-life stories, first-person perspectives, and expert-backed information. Our ...

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...